Elba Margarita Romero Tejeda

Elba Margarita Romero Tejeda

Auto-generated profile, based on publicly available information

Elba Margarita Romero Tejeda

Departamento de Farmacobiología, Centro Universitario de Ciencias Exactas e Ingenierías, UdeG

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HCHeriberto Jacobo Cuevas
Heriberto Jacobo Cuevas
Edsaul Emilio Perez-GuerreroEdsaul Emilio Perez-Guerrero
Edsaul Emilio Perez-Guerrero
ECEsther G. Corona-Sanchez
Esther G. Corona-Sanchez
ERElba M. Romero-Tejeda
Elba M. Romero-Tejeda
STSylvia Elena Totsuka
Sylvia Elena Totsuka
JGJorge I. Gamez-Nava
Jorge I. Gamez-Nava
There is a significant rate of therapeutic failure in rheumatoid arthritis (RA) patients treated with leflunomide (LEF). This study investigates the utility values of teriflunomide levels (A77 1726) in identifying RA patients who remained with moderate or severe disease activity after the treatment with LEF. In this cross-sectional study, we compared: (a) RA patients who achieved a DAS28-ESR ≤ 3.2, and (b) RA patients who maintained a DAS28-ESR > 3.2 after treatment. ROC curves determined the cut-off of A77 1726 with the better performance to identify patients achieving a DAS28-ESR ≤ 3.2. Of the 115 patients treated with LEF, 69 (60%) remained with moderate/severe disease activity and 46 (40%) achieved low disease activity/remission. Higher A77 1726 levels showed a negative correlation with DAS28-ESR (r = − 0.42, p < 0.001) and other parameters of disease activity. We obtained the following utility values with the cut-off of A77 1726 > 10 µg/mL to identify RA patients who achieved a DAS28-ESR ≤ 3.2: sensitivity of 91.31%; specificity of 73.91%; positive predictive value of 70.00%; and negative predictive value of 92.73%. Serum A77 1726 discriminated between RA patients who remained with moderate/severe disease activity despite the treatment with LEF both as monotherapy and LEF as combo therapy.

13 April 2022 in International Journal of Analytical Chemistry
Verified
Journal Article
Open access
PDF file
CMCLAUDIA VERONICA PALACIOS MAGAÑA
CLAUDIA VERONICA PALACIOS MAGAÑA
ERElba M. Romero-Tejeda
Elba M. Romero-Tejeda
NFNicte Selene Nicte Selene Fajardo-Robledo
Nicte Selene Nicte Selene Fajardo-Robledo
LOLuis Javier González Ortiz
Luis Javier González Ortiz
JGJosé G González-Mendez
José G González-Mendez
FPFermin Paul Pacheco-Moises
Fermin Paul Pacheco-Moises
A sensitive and efficient analytical process for detecting lamotrigine in acidic solution based in ultra-high-performance liquid chromatography-diode array detector (UPLC-DAD) was developed; the stationary phase used was a C8, 150×4.6mm, 2.6µm. The mobile phase consisted of acetonitrile/acidified water (0.01 H3PO4 and 0.005 triethylamine, pH 2.4) (25:75 v/v). Limits of detection and quantification were 0.02µg/mL and 0.05µg/mL, respectively. The working interval for the evaluation of the method ranged from 0.05 to 12µg/mL, and the linear fit of the experimental data has a value of r20.98. Before quantifying lamotrigine in plasma of patients with bipolar disorder, lamotrigine was released from plasma proteins with a 0.2M sodium hydroxide solution, and then proteins were removed by precipitation with acetonitrile. Afterward, the lamotrigine base was dissolved in ethyl acetate. This extract was reconstituted in potassium phosphate solution (pH 2.4) to obtain more than 98 of lamotrigine protonated in N2, which was detected and quantified as indicated above. The absolute percentage of lamotrigine recovery is 80 for all tested concentration levels. The accuracy and precision of the method have CV values 4 for the lamotrigine levels of 3, 6, and 9µg/mL. The correlation coefficient for the used concentration range is 0.99. The analytical method is precise and sensitive to measure lamotrigine levels expected in plasma of BD patients and these levels were in the therapeutic dose range.

12 January 2026 in Acta Pediátrica de México
Verified
Journal Article
Open access
PDF file
JLJuan Antonio Garzón Lamarque
Juan Antonio Garzón Lamarque
CNCristhian Daniel Escalante Navarro
Cristhian Daniel Escalante Navarro
ARAngelica Berenice Becerra Ruiz
Angelica Berenice Becerra Ruiz
FZFernando Antonio Sánchez Zubieta
Fernando Antonio Sánchez Zubieta
ETElba Margarita Romero Tejeda
Elba Margarita Romero Tejeda
MZMonzerrat Pardo Zepeda
Monzerrat Pardo Zepeda
INTRODUCCIÓN: El reporte sistemático de Sospechas de Reacciones Adversas a Medicamentos (SRAMs) es fundamental para la seguridad del paciente, ya que, permite identificar patrones y adoptar medidas preventivas. OBJETIVO: Analizar los reportes de las SRAMs en pacientes pediátricos con Leucemia Linfoblástica Aguda (LLA) tratados bajo el protocolo MAS-ALL18 en el Hospital Civil Nuevo de Guadalajara ‘Dr. Juan I. Menchaca’, con el fin de caracterizar los reportes de SRAMs, evaluar las asociaciones entre medicamentos específicos y SRAMs, analizar asociaciones entre gravedad y sexo, y determinar la causalidad mediante criterios estandarizados. MATERIALES Y MÉTODOS: Estudio observacional, retrospectivo y analítico, basado en reportes de SRAMs. Se realizaron análisis descriptivos y bivariado para identificar asociaciones entre las variables de interés. Se recopilaron y analizaron notificaciones reportes de SRAMs a través del sistema de reporte del hospital. RESULTADOS: Se incluyeron un total de 149 pacientes. En ellos se reportaron 602 SRAMs, un promedio de 4 SRAMs por paciente. Las reacciones más frecuentes fueron neutropenia febril, mucositis, vómito, leucopenia, anemia, trombocitopenia y náuseas. Además, se encontró una relación entre la gravedad de las SRAMs reportadas y el sexo. CONCLUSIONES: El análisis de reportes de SRAMs en pacientes pediátricos tratados bajo el protocolo MAS-ALL18 en nuestra unidad de oncología permitió identificar SRAMs frecuentes, asociaciones con medicamentos específicos y variaciones de la gravedad según el sexo. Los hallazgos, respaldados por análisis estadísticos y criterios estandarizados de causalidad, ofrecen evidencia relevante para fortalecer la farmacovigilancia y mejorar la seguridad del tratamiento.